Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Nishaanth Dalavaye, Simon Erridge, Martha Nicholas, Manaswini Pillai, Lara Bapir, Carl Holvey, Ross Coomber, James J Rucker, Jonathan Hoare & Mikael H Sodergren. (2023) The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry. Expert Review of Gastroenterology & Hepatology 17:1, pages 85-98.
Read now
Read now
Articles from other publishers (21)
Lucy Williamson. (2022) A holistic approach to the treatment of Crohn's disease and ulcerative colitis. British Journal of Healthcare Management 28:7, pages 163-166.
Crossref
Crossref
Dominic King, Raoul C. Reulen, Tom Thomas, Joht Singh Chandan, Rasiah Thayakaran, Anuradhaa Subramanian, Krishna Gokhale, Neeraj Bhala, Krishnarajah Nirantharakumar, Nicola J. Adderley & Nigel Trudgill. (2020) Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018. Alimentary Pharmacology & Therapeutics 51:10, pages 922-934.
Crossref
Crossref
Lindsay Bottoms, Dean Leighton, Roger Carpenter, Simon Anderson, Louise Langmead, John Ramage, James Faulkner, Elizabeth Coleman, Caroline Fairhurst, Michael Seed & Garry Tew. (2019) Affective and enjoyment responses to 12 weeks of high intensity interval training and moderate continuous training in adults with Crohn’s disease. PLOS ONE 14:9, pages e0222060.
Crossref
Crossref
Stuart A Taylor, Sue Mallett, Gauraang Bhatnagar, Stephen Morris, Laura Quinn, Florian Tomini, Anne Miles, Rachel Baldwin-Cleland, Stuart Bloom, Arun Gupta, Peter John Hamlin, Ailsa L Hart, Antony Higginson, Ilan Jacobs, Sara McCartney, Charles D Murray, Andrew AO Plumb, Richard C Pollok, Manuel Rodriguez-Justo, Zainib Shabir, Andrew Slater, Damian Tolan, Simon Travis, Alastair Windsor, Peter Wylie, Ian Zealley & Steve Halligan. (2019) Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn’s disease patients: the METRIC diagnostic accuracy study. Health Technology Assessment 23:42, pages 1-162.
Crossref
Crossref
Cláudia Camila Dias, Mafalda Santiago, Luís Correia, Francisco Portela, Paula Ministro, Paula Lago, Eunice Trindade, Alberto Freitas & Fernando Magro. (2019) Hospitalization trends of the Inflammatory Bowel Disease landscape: A nationwide overview of 16 years. Digestive and Liver Disease 51:7, pages 952-960.
Crossref
Crossref
Shellie Jean Radford. (2019) Fatigue in inflammatory bowel disease: understanding research needs through an exploratory narrative review. Gastrointestinal Nursing 17:4, pages 30-35.
Crossref
Crossref
Thomas Langford, Zehra Arkir, Anastasia Chalkidou, Kate Goddard, Lamprini Kaftantzi, Mark Samaan & Peter Irving. (2018) The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study. JMIR Research Protocols 7:10, pages e11218.
Crossref
Crossref
Matthew Strohl, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow & Peter L Lakatos. (2018) Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?. World Journal of Gastroenterology 24:22, pages 2363-2372.
Crossref
Crossref
. (2016) UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 4:5_suppl, pages A157-A720.
Crossref
Crossref
Katharina Büsch, Simone A. da Silva, Michelle Holton, Fabiana M. Rabacow, Hamed Khalili & Jonas F. Ludvigsson. (2014) Sick leave and disability pension in inflammatory bowel disease: A systematic review. Journal of Crohn's and Colitis 8:11, pages 1362-1377.
Crossref
Crossref
Madhoor RamdeenAndrew PoullisSachin GuptaDeb Ghosh. (2014) Motivational interviewing to improve inflammatory bowel disease outcomes. Gastrointestinal Nursing 12:4, pages 15-22.
Crossref
Crossref
Keith Bodger, Linnette Yen, Agota Szende, Gunjan Sharma, Yaozhu J. Chen, John McDermott & Paul Hodgkins. (2014) Medical resource utilization and associated costs in patients with ulcerative colitis in the UK. European Journal of Gastroenterology & Hepatology 26:2, pages 213-221.
Crossref
Crossref
Jonathan Ariyaratnam & Venkataraman Subramanian. (2014) Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis. American Journal of Gastroenterology 109:2, pages 163-169.
Crossref
Crossref
G. W. Moran, A. W. K. Lim, J. L. Bailey, M.-F. Dubeau, Y. Leung, S. M. Devlin, K. Novak, G. G. Kaplan, M. Iacucci, C. Seow, L. Martin, R. Panaccione & S. Ghosh. (2013) Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 38:9, pages 1002-1024.
Crossref
Crossref
Laith Alrubaiy, Ian Arnott, Aimee Protheroe, Michael Roughton, Richard Driscoll & John G Williams. (2013) Inflammatory bowel disease in the UK: is quality of care improving?. Frontline Gastroenterology 4:4, pages 296-301.
Crossref
Crossref
Abhinav Vasudevan, Asiri Arachchi & Daniel R. van Langenberg. (2013) Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: A small step for clinicians, a potentially large step for improving quality of care. Journal of Crohn's and Colitis 7:9, pages e367-e374.
Crossref
Crossref
Amosy E. M'koma. (2013) Inflammatory Bowel Disease: An Expanding Global Health Problem. Clinical Medicine Insights: Gastroenterology 6, pages CGast.S12731.
Crossref
Crossref
Antony Cutler, John Girdlestone, Sally Hopewell, Simon Stanworth, Carolyn Doree, Francesco Dazzi, Vipul Jairath & Cristina Navarrete. (2012) Mesenchymal stromal cells (MSC) for treating immune-mediated inflammation post-transplantation and in autoimmunity. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Keith Bodger. (2011) Cost Effectiveness of Treatments for Inflammatory Bowel Disease. PharmacoEconomics 29:5, pages 387-401.
Crossref
Crossref
A. BUCKLAND & K. BODGER. (2008) The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics 28:11-12, pages 1287-1296.
Crossref
Crossref
Gary R. LichtensteinRemo Panaccione & Gordon Mallarkey. (2008) Review: Efficacy and safety of adalimumab in Crohn's disease. Therapeutic Advances in Gastroenterology 1:1, pages 43-50.
Crossref
Crossref